Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Desvenlafaxine Clear all
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT00797966
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
OPC-34712, Placebo, ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
50
States / cities
Arcadia, California • Beverly Hills, California • Escondido, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)

NCT00440427
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Desvenlafaxine Sustained Release (DVS SR)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2007 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY03005 vs Pristiq

NCT03733574
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY03005, Pristiq
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

NCT01715805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women

NCT00369434
View directory record Official record
Conditions
Menopause, Vasomotor System
Interventions
Desvenlafaxine succinate sustained-release (DVS SR)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
Female only
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
34
States / cities
Montgomery, Alabama • Peoria, Arizona • Upland, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 31, 2007 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

NCT03357796
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY03005, Pristiq
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 4 Interventional Results available

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

NCT02058693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
mixed salts amphetamine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 2Phase 3 Interventional Results available

TRIAD - Treatment of Insomnia and Depression

NCT00767624
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Depression
Interventions
Antidepressant, Desensitization Therapy for Insomnia, Cognitive Behavioral Therapy for Insomnia
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Stanford, California • Durham, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

NCT00863798
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release 10mg, Desvenlafaxine Succinate Sustained-Release 50 mg, placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Birmingham, Alabama • Encino, California • Newport Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 5, 2011 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

NCT01371708
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
DVS SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
35
States / cities
Birmingham, Alabama • Tucson, Arizona • Imperial, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

NCT00798707
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release (DVS SR), placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Arcadia, California • Beverly Hills, California • Cerritos, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects

NCT00727064
View directory record Official record
Conditions
Healthy
Interventions
Desvenlafaxine Succinate Sustained-Release (DVS SR), Venlafaxine Extended Release (VEN ER)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2010 · Synced Sep 1, 2026, 10:26 PM EDT
Completed No phase listed Observational

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

NCT06049797
View directory record Official record
Conditions
Hot Flashes
Interventions
Fezolinetant, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Lomita, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects

NCT01189500
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Tamoxifen, Tamoxifen and Desvenlafaxine Succinate Sustained Release
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects

NCT01188668
View directory record Official record
Conditions
Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human
Interventions
Aripiprazole, Aripiprazole + desvenlafaxine succinate sustained release
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

NCT00384033
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Desvenlafaxine Succinate Sustained-Release (DVS SR), Placebo, Duloxetine 60 mg/day
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
638 participants
Timeline
2006 – 2007
U.S. locations
22
States / cities
Beverly Hills, California • Burbank, California • Encino, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 4 Interventional Results available

Desvenlafaxine vs. Placebo Treatment of Chronic Depression

NCT01537068
View directory record Official record
Conditions
Dysthymic Disorder, Dysthymia, Chronic Depressive Disorder
Interventions
Desvenlafaxine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
20 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 3 Interventional

Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder

NCT00277823
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
DVS-SR 50 mg, DVS-SR 100 mg, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Beverly Hills, California • Northridge, California • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects

NCT00329186
View directory record Official record
Conditions
Healthy
Interventions
desvenlafaxine SR, venlafaxine ER
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam

NCT00952653
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained Release, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2011 · Synced Sep 1, 2026, 10:26 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

NCT01803711
View directory record Official record
Conditions
Major Depression, Cancer, Diabetes, Cardiovascular Diseases
Interventions
Desvenlafaxine, Omega 3 Fatty acids, Placebo (for Omega 3 fatty acid supplement)
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

NCT04476030
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
51
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics Study of LY03005

NCT02055300
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY03005, Placebo, Meal, Pristiq
Drug · Other
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2014 · Synced Sep 1, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women

NCT00683800
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
desvenlafaxine succinate (DVS) SR, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years and older · Female only
Enrollment
2,186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2011 · Synced Sep 1, 2026, 10:26 PM EDT